Immune disease variants modulate gene expression in regulatory CD4⁺ T cells

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Disease-associated genetic variants can dysregulate cellular functions, offering potential therapeutic targets.
• Studying immune diseases often involves CD4+ regulatory T (Treg) cells, but these cells can be difficult to sample for research.
• Understanding genetic influences on Treg cell function is crucial for developing new treatments for immune disorders.

Purpose of the Study:

• To map the genetic regulation of gene expression and chromatin activity in Treg cells.
• To identify overlaps between genetic loci associated with immune diseases and Treg cell regulatory elements.
• To discover novel drug targets and assess drug tractability for immune disease therapies.

Main Methods:

• Quantitative trait loci (QTL) mapping of gene expression and chromatin activity in Treg cells.
• Colocalization analysis of Treg cell QTLs with immune disease genome-wide association study (GWAS) variants.
• Identification and evaluation of potential drug targets within significant GWAS loci.

Main Results:

• 133 colocalizing loci were identified between immune disease variants and Treg cell QTLs.
• Colocalization with expression QTLs (eQTLs) for CD28 and STAT5A supports Treg cell involvement in immune disease pathobiology.
• Seven known drug targets were identified for repurposing, and 63 additional tractable targets were suggested.

Conclusions:

• This study provides the first in-depth analysis of how immune disease variants affect Treg cell gene expression and function.
• The findings highlight the critical role of Treg cells in immune disease mechanisms.
• The identified targets offer promising avenues for drug repurposing and the development of novel cell therapies for immune diseases.